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ABSTRACT

Compositions of matter and methods of treating cancer
patients may prevent or limit cardiotoxicity during or after
chemotherapy, and/or may prevent or lower resistance to
anthracycline drugs, both of which are believed to be caused
by the human enzyme carbonyl reductase. Thus, the compositions and methods may be used to reduce the dosages of
anthracycline anti-cancer drugs necessary to produce a
desired cancer-cell-killing performance. Preferred embodiments comprise treating cancer patients with a pharmaceutical composition comprising biphenyl compounds having two
halogenated (or pseudo-halogenated) and/or hydroxylated,
aryl groups that are linked by a bridging atom. The preferred
composition of biphenyl compound(s) may be administered
in a pharmaceutical composition also comprising at least one
anthracycline compound, or may be administered separately
than the at least one anthracycline compound. Especiallypreferred biphenyl compounds include triclosan, hexachlorophene, and dichlorophene.
9 Claims, 9 Drawing Sheets
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Inhibition Pattern
Compouud
K i., (~M)
KH,(I-lMl
-lIexachlorophene Uncompetitive"'O
12 ± 1
(Fig. I, C.)
78 ± 8
Dichlorophene Noncompetitive"'C
40± 8
(Fig. 2, D.).
Uncompetitive",a
20 ± 1
Dichlorophene
(Fig. 2, D.).
Uncompetitive",b
0.23 ± 0,01
Triclosan
-(Fig. 3, E.)
"Studies were done with a fixed NADPH concentration of 50 ~M, varied menadione concentrations ranging
from 12 to 125 )lM in 100 mM sodium phosphate buffer, pH=7,O,
VA
bData fit best to the uncompetitive inhibition model va =
I
where A is the concentration of
A(1 +-) + Kill

Kii
menadione, I is the inhibitor concentration, V is the maximal velocity, Km is the Michaelis constant for
menadione and Kii is the intercept inhibition constant.
CD ata fiIt b est to th e noncompehtive
"
1'nh'b"
1 l110n mo deI

Va

=

I

VA

I

where A is the

A(1 + - ) + K", (1 +-)
Kii
K is
concentration of menadione, I is the inhibitor concentration, V is the maximal velocity, Km is the Michaelis
constant for menadione, Kii is the intercept inhibition constant, and Kis is the slope inhibition constant.
d Study done with a fixed NADPH concentration of 300 )lM and varied menadione as previously described,

Fig. 7

~

7Jl
•
~

~

I

I NADPH (A) I IMenadiO~e (B) I

[!]

1

lEAl

t

~

1

Menadiol (P)

•

[EAB~EPQI

t
and/or

[ EPQI

Fig. 8

I

I

I I

NADP+ (Q)

IEQI

t

and/or

I EQI

I

I

~

~

=
~

>
=
~

[!]

...

N
~
N
0

....

0

rFJ

=-

('D
('D

.....

QO

....

0

\0

u.s. Patent

Aug. 24, 2010

US 7,781,412 B2

Sheet 9 of 9

400
350

~

=....=

300

U
~

250

It'l

.9y
.,.

,Q

=

200
150

J-t

0

~

100

~

50

0

0
0

40

60

[Triclosan], JlM

Fig. 9

80

US 7,781,412 B2
1

2

BIPHENYL INHIBITORS OF CARBONYL
REDUCTASE

is largely because the alcohol metabolites of anthracyclines
have been shown to exhibit significantly lowered anticancer
properties. Relevant to this are studies performed by Tanaka,
et aI., (reported in Tanaka, et aI., "An Unbiased Cell Morphology-Based Screen for New, Biologically Active Small Molecules," PLoS Biology, Vol. 3, Iss. 5, 0764-0776, May 2005).
Tanaka, et al. report that a potent inhibitor of human carbonyl
reductase (3 -(7 -isopropy1-4-(methylamino )-7H -pyrrolo [2,3d]pyrimidin-5-yl) phenol, when coadministered with daunorubicin to A549 adenocarcinoma cells, was found to enhance
the cytotoxicity of daunorubicin. It was concluded that inhibition of carbonyl reductase led to enhanced cytotoxicity of
daunorubicin.
See, for example, the FIG. 2 representation of carbonyl
reductase catalysis (reduction via NADPH+H+ mechanism)
of the anthracycline daunorubicin to daunorubicinol. While
daunorubicin is an effective anti-cancer agent by means of its
effective disruption of DNA replication, daunorubicinol
exhibits reduced anti-cancer properties and is a potent cardiotoxin. Therefore, conversion to the alcohol metabolite not
only creates a potent cardiotoxin, but also lowers the efficacy
of the treatment for a given amount of anthracycline.
Therefore, the inventor believes that there is a need for
pharmaceutical interventions that block the action of human
carbonyl reductase. The inventor believes that such pharmaceutical interventions will increase the efficacy of anthracycline therapy in cancer/tumor treatment by preventing or lowering conversion of anthracyclines to less potent cell-killing
species and by reducing the risk of cardiotoxicity.

Some activities related to this invention were conducted
with support by National Institute of Health, NIH/
P20RR16454.
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to compositions of matter, and methods of using said compositions for inhibiting enzyme(s) that
destroy the cell-killing efficacy of cancer drugs and/or that
catalyze the formation of dangerous or damaging metabolites
during or after cancer treatment. More specifically, preferred
embodiments of the invented compositions and methods
inhibit human carbonyl reductase, thus inhibiting conversion
of anthracycline to metabolites that are less effective cellkilling agents and that also lead to cardiotoxicity during or
after treatment of cancer patients. Thus, the preferred compositions and methods are believed to lower the amount
needed, and the cardiotoxic side-effects, of anthracyclines in
cancer treatment.
2. Related Art
Anthracyclines are a family of drugs that are effective
anti-neoplastic agents, and are commonly used to treat cancer, including leukemia, soft tissue sarcomas, and breast and
lung cancer. Anthracyclines intercalate into DNA and are
described as topoisomerase Type II poisons. The anthracycline family comprises adriamycin, daunomycin, daunorubicin, doxorubicin, epirubicin, and idarubicin. See, for
example, representations of doxorubicin and daunorubicin in
FIG. 1.
While the anthracyclines are known to be potent anti -tumor
drugs, their use has been limited due to potentially life-threatening cardiotoxicity associated therewith. This problem may
be described as cumulative dose-dependent cardiotoxicity,
which can ultimately result in congestive heart failure. There
is significant evidence that the toxic effects on the heart associated with anthracycline-based cancer treatment are largely
attributable to anthracycline alcohol metabolite(s) that can
form and accumulate in cardiac cells. These metabolites are
known to disrupt several key processes in heart muscle and
thus impair heart function. See, for example, Minotti, et aI.,
"Anthracyclines: Molecular Advances and Pharmacologic
Developments in Antitumor Activity and Cardioitoxicity,"
Pharmacological Reviews, 56: 185-229,2004.
Enzymes belonging to the aldo-keto reductase and short
chain dehydrogenase/reductase protein superfamilies catalyze the formation of the anthracycline metabolites. Of these
enzymes, carbonyl reductase ("CR") has been specifically
linked to the development of anthracycline-induced cardiotoxicity. See, for example, Olson, et aI., "Protection from
Doxorubicin-Induced Cardiac Toxicity in Mice with a Null
Allele of Carbonyl Reductase 1," Cancer Research, 63,66026606, Oct. 15,2003. Findings that support the hypothesis that
CR is a key factor in anthracycline-induced cardiotoxicity
include studies wherein heart-specific over-expression of
human carbonyl reductase in transgenic mice substantially
increased the development of cardiotoxicity after anthracycline treatment. See, for example, Forrest, et aI., "Human
Carbonyl Reductase Overexpression in the Heart Advances
the Development of Doxorubicin-induced Cardiotoxicity in
Transgenic Mice," Cancer Research, 60,5158-5164, Sep. 15,
2000.
Further, several studies have implicated the reduction of
anthracyclines by carbonyl reductase in drug resistance. This
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The present invention comprises compositions of matter
that include inhibitors of human enzymes. The preferred
embodiments comprise compositions of matter, and methods
of treating patients, that prevent or lower conversion in the
human body of cancer drugs to metabolites that are less
effective for cancer treatment and/or that are believed to produce cardiotoxicity during or after cancer treatment. Hence,
by using preferred embodiments of the invented compositions and/or methods, the effectiveness of a given dose of
anthracycline drugs may increase, and the risk of cardiotoxicity typically associated with said treatment may lessen.
Embodiments of the invention may comprise compositions
or treatments for, and/or methods of, inhibiting one or more
enzymes from the groups referred to as aldo-keto reductase
and short chain dehydrogenase/reductase protein superfamilies. Preferably, embodiments of the invention comprise compositions or treatments for, and/or methods of, inhibiting
enzyme(s) that catalyze anthracycline conversion to anthracycline metabolites, wherein carbonyl reductase ("CR") is
especially implicated as described in the Related Art section
above. Preferably, this inhibition also has the direct effect of
maintaining concentrations of anthracyclines, which are
desirable for their cell-killing abilities, and, hence, for their
cancer-cell-killing abilities. Preferably, this inhibition also
has a indirect effect oflowering formation of metabolites that
build up during or after treatment with anthracycline cancer
drugs, said metabolites being ones that are believed to disrupt
heart muscle processes and therefore to interfere with heart
function. Therefore, by using preferred embodiments of the
invented compositions and/or methods, much less anthracycline drug is expected to be needed to achieve the desired
killing of cells, and much less cardiotoxic metabolite will be
produced over the duration of the cancer treatment.
The invented compositions comprise compounds having at
least one aryl (preferably phenyl) group, wherein at least one
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of said at least one aryl/phenyl group comprises one or more
halogen, pseudo-halogen, and/or hydroxyl group. In the preferred embodiments disclosed herein, the compositions comprise compounds having at least two aryl (preferably phenyl)
groups, wherein at least one of said at least two aryl/phenyl
groups comprises one or more halogen, pseudo-halogen, and/
or hydroxyl group.
In especially-preferred embodiments, two halogenated,
pseudo-halogenated and/or hydroxylated aryl/phenyl groups
are connected by a bridging carbon, oxygen, sulfur, nitrogen,
or derivative of carbon, oxygen, sulfur, or nitrogen, wherein at
least one of said aryl/phenyl groups comprises at least one
halogen, pseudo-halogen, or hydroxyl group. Especially-preferred embodiments comprise one or more biphenyl componnds selected from the group consisting of: triclosan,
hexachlorophene, dichlorophene, bithionol, bithionol sulfoxide, and derivatives thereof. The biphenyl componnds may be
administered to a human (or other mammal) in a pharmaceutical composition also comprising at least one anthracycline
compound, or may be administered separately from the at
least one anthracycline componnd either at the same time as
the anthracycline(s), or any different time found to be effective for inhibiting formation of the anthracycline metabolites.
Therefore, an object of the preferred embodiments is to
inhibit one or more of the members of the aldo-keto reductase
and/or short chain dehydrogenase/reductase protein superfamilies that catalyze conversion of anthracycline to anthracycline metabolites. The preferred embodiments inhibit
human carbonyl reductase and are expected to produce the
synergistic effects of reducing cardiotoxicity from anthracycline chemotherapy and also lowering dosages of the anthracycline drug that will be effective for cancer-cell-killing.

FIG. 8 snnnnarizes data showing that all of the inhibitors
bind to enzyme forms distinct from those to which menadione
binds, as determined from inhibition studies such as those
represented in FIGS. 4-7. The inhibitors (represented by "I")
dichlorophene, hexachlorophene, and triclosan may bind to
free enzyme, ternary and/or the enzyme-NADP+ binary complex. Enzyme (CR) is represented by "E". Menadione could
be replaced by anthracyclines or other carbonyl-containing
substrates, so that menadione may be considered a substitute
or surrogate for anthracyclines or other carbonyl-containing
substrates in these studies.
FIG. 9 shows a graph indicating that addition of increasing
concentrations oftriclosan lowers the IC so of doxorubicin in
killing breast cancer cells (MDA cell line). Cell viability was
determined by uptake of alomar blue.
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FIG. 1 is a representation of an anthracycline compound,
which may be doxorubicin (R OH) or daunorubicin
(R H), wherein the arrow designates the carbon at position
13.
FIG. 2 is a representation of a carbonyl reductaseNADPH mechanism for reducing the anthracycline dannorubicin to the anthracycline alcohol metabolite dannorubicinol.
FIGS. 3A-F show the chemical structures of several biphenyl inhibitors (FIGS. 3A-E) of carbonyl reductase according
to embodiments of the invention and a representation of a
general structure (FI G. 3 F) expected to lead to other carbonyl
reductase inhibitors with the scope of the invention. FIGS.
3A-E illustrate: 3A. Bithionol, 3B. Bithionol Sulfoxide, 3C.
Hexachlorophene, 3D. Dichlorophene, and 3E. Triclosan. In
the representation of a general structure of FIG. 3F, R1=C, S,
0, N and all derivatives; R2=hydrogen, halogen, alcohol,
pseudohalogen; and carbons in the phenyl ring may also be
replaced by N, S, and/or O.
FIG. 4 is a graph showing that dichlorophene is a noncompetitive inhibitor against menadione, when the NADPH concentration is fixed at 50 flM.
FIG. 5 is a graph showing that hexachlorophene is an
uncompetitive inhibitor against menadione, when the
NADPH concentration is fixed at 50 flM.
FIG. 6 is a graph showing that triclosan is an nncompetitive
inhibitor against menadione, when the NADPH concentration is fixed at 50 flM.
FIG. 7 describes inhibition patterns seen with inhibitors
dichlorophene, hexachlorophene, and triclosan wherein KIS
and KII stand for the slope and intercept inhibition constants,
respectively.
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Referring to the figures, there are shown several, but not the
only, embodiments of the invented composition of matter and
methods for enhancing the efficacy of anthracycline drug
cancer treatment and/or limiting side-effects thereof. The
preferred methods and compositions of matter may maintain
effective concentrations of anthracycline(s) during cancer
treatment, by preventing or lowering conversion of the
anthracycline(s) to metabolites that are less effective or ineffective as cancer-cell-killing species. The preferred methods
and compositions may also prevent or lower the potentially
life-threatening cardiotoxicity associated with anthracycline
chemotherapy for cancer patients.
Some embodiments of the invention may include compositions, and/or methods of using the compositions in cancer
treatment, that comprise one aryl (preferably phenyl) group,
for example, a halogenated aryl group, oximino(2,4-difluorophenyl)acetonitrile, oximino(2,6-difluorophenyl)acetonitrile, oximino(2,5-difluorophenyl)acetonitrile, oximino(2chloro-6-fluorophenyl)acetonitrile,
oximino(2,4dichlorophenyl)acetonitrile, oximino(2,6-dichlorophenyl)
acetonitrile, and/or mixtures of two or more thereof, as
disclosed in Patent Application Ser. No. 60/830,293 and Ser.
No. 111776,536. However, embodiments of the invention that
are expected to show superior results in the treatment of
cancer may be described as those comprising at least two
(preferably two) aryl or phenyl groups, and, especially, those
that are disclosed in Patent Application Ser. No. 601776,269
and Ser. No. 111711,490 and that are disclosed herein. Therefore, the preferred compounds that are expected to provide
superior results for use in the above-described prevention or
lowering of anthracycline conversion have at least two aryl
(preferably phenyl) groups, wherein at least one of the aryl/
phenyl groups has at least one halogen, pseudo-halogen or a
hydroxyl group as a substituent. Pseudo-halogens may
include binary inorganic compounds of the general form XY,
where X is a cyanide, cyanate, or thiocyallate and where Y is
any of X or a true halogen, including but not limited to
cyanogen ((CN)2) and iodine cyanide (lCN). Preferably,
biphenyl componnds that are halogenated or pseudo-halogenated also comprise at least one hydroxyl group.
The especially-preferred embodiments comprise one or
more substituted biphenyl compounds, and preferably one or
more of the following compounds: triclosan, hexachlorophene, dichlorophene, and, as previously described in
Patent Application Ser. No. 601776,269 and Ser. No. 111711,
490, bithionol, bithionol sulfoxide, and derivatives thereof.
See FIGS. 3A-E. Also, it is expected that derivatives or analogs of these compounds may be effective in the place of one
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or more of these compounds, or as a supplement to one or
more of these compounds. Considering the structures of the
triclosan, hexachlorophene, and dichlorophene and bithionol
and bithionol sulfoxide from patent application Ser. No.
111711,490, an overall general structure (biphenyl compound) for possible carbonyl reductase inhibitors is envisioned. This biphenyl compound general structure is depicted
in FIG. 3F and compounds fitting this general structure are
also expected to prevent or hinder anthracycline conversion in
embodiments of the invention.
The compounds and general structure illustrated in FIGS.
3A-F may further be described by the following Table 1:

In addition, because the anthracycline metabolite(s) are
believed to not possess the anti-neoplastic properties of the
parent anthracycline(s), carbonyl reductase may also contribute to anthracycline drug resistance. In other words, carbonyl
reductase may lower anthracycline concentrations in the
human body by catalyzing conversion of the anthracycline,
and, hence, may lower the amount of cancer cells killed by a
given dose of anthracycline drug.
Several biphenyl compounds, namely, triclosan, hexachlorophene, dichlorophene and those identified in Ser. Nos.
601776,269 and Ser. No. 111711,490, have been shown by the
inventor to inhibit carbonyl reductase, and are envisioned to
allow an increase in anthracycline chemotherapy by offsetting the negative side effects of this chemotherapy. Also, as
discussed above, the preferred compositions and methods
may decrease anthracycline drug resistance, further improving the results of anthracycline chemotherapy.
Specifically, referring to FIGS. 4-6, triclosan, hexachlorophene, and dichlorophene have been shown by the inventors to be uncompetitive inhibitors (noncompetitive for
dichlorophene) carbonyl substrates, with inhibition constant
values ranging from 0.23-78 flM. These preferred compounds
have been seen to exhibit inhibition patterns suggestive of
binding to multiple enzyme forms, which may mean that
increased anthracycline dosages may not overcome the inhibition. See FIGS. 4-6, which comprise data from laboratory
testing using menadione. Menadione could be replaced by
anthracyclines or other carbonyl-containing substrates, so
that menadione may be considered a substitute or surrogate
for anthracyclines or other carbonyl-containing substrates in
these studies, and, hence, indicative of expected performance
regarding anthracyclines.
Triclosan, hexachlorophene, and dichlorophene are known
antibiotics. For examples see the following literature:
Kim, Woo-Jae; Oh, Nam-Hun; Park, Seung-Kyu; Kim,
Jeong-Cheol. Antimicrobial composition comprising silver
zeolite, Houttuynia cordata extract and triclosan, filter for
indoor air quality applying the same and manufacturing
method thereof. PCT Int. Appl. (2007), 16 pp. CODEN:
PIXXD2 WO 2007074957 Al 20070705 CAN 147:125938
AN 2007:728884;
Belcheva, Nadya; Kennedy, John. Antimicrobial medical
devices with adherence-enhancing agents. U.S. Pat. Appl.
Publ. (2007), 8 pp. CODEN: USXXCO US 2007207189 Al
20070906 AN 2007:993759.
Knappenberger, Kyle; Martin, Lisa; Malchesky, Paul S.
Organic biocidal decontamination compositions. PCT Int.
Appl. (2006),19 pp. CODEN: PIXXD2 WO 2006085975A2
20060817 CAN 145:235978 AN 2006:817656.
Also triclosan, hexachlorophene, and dichlorophene are
known anti-neoplastic agents. See, for example:
Fischer, Frank J.; Miller, Jessica Watts; Andrews, Marvin
O. Implantable medical device with anti-neoplastic drug.
U.S. Pat. Appl. Publ. 200652757 (Mar. 9,2006), 12 pp.,
Oh, Sang Taek. Pharmaceutical composition for treating
cancer containing hexachlorophene capable of inhibiting
wntlbeta-catenin response transcription. Repub. Korean
Kongkae Taeho Kongbo (2006), No pp. given. CODEN:
KRXXA7 KR2006124031A20061205 CAN 147:79443AN
2007:703062.
Westwick, John K.; Yu, Helen; Owens, Stephen; MacDonald, Mamie L. Drugs for the treatment of neoplastic
disorders. (Odyssey Thera, Inc., USA). U.S. Pat. Appl. Publ.
20060009506 (Jan. 12,2006),21 pp. CODEN: USXXCO US
2006009506 Al 20060112.
To the inventors' knowledge, however, triclosan, hexachlorophene, or dichlorophene have not been used in any process
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TABLE 1
15
Figure No.

Names

3A

Bithionol, 2,2'-Thio-bis(4,6-dichlorophenol),
Bis(2-hydroxy-3 ,5-dichlorophenyl) sulfide
Bithionol Sulfoxide, 2,2'-Sulfinyl-bis (4,6dichlorophenol)
Hexachlorophene,2,2'-Methylenebis(3,4,6trichlorophenol)
Dichlorophene, Bis(5-chloro-2-hydroxphenyl)methane,
Dichlorophen
Triclosan,5-Chloro-2-(2,4-dichlorophenoxy)phenol,
Irgasan
A General Structure, wherein Rl = C, S, 0, N
and/or all derivatives; wherein R2 = hydrogen,
halogen, alcohol (hydroxyl), and/or pseudohalogen;
and wherein carbons in the phenyl ring may be replaced by N, Sand/or O. (Note that, while the ring
structures of FIG. 3F are portrayed in the conventional manner as six- carbon ring structures, one
or more of the carbons of one or both of said sixcarbon ring structures may be replaced by nitrogen,
sulfur, and/or oxygen, and may not have hydrogen or
substituent groups).

3B
3C
3D
3E
3F

20

25

30

35

It may be noted that carbon of the aryl/phenyl rings shown
in FIG. 3F may be replaced by N, S, and/or O. It may also be
noted that one or more halogen, pseudo-halogen and/or alcohol groups may be substituent groups bound to all or some of
the carbons of one or both of the aryl/phenyl rings of the
preferred compounds, but that carbon sites (carbons of the
aryl-phenyl rings) may also have no substituent group (hence,
"unsubstituted") and would comprise hydrogen bound to said
carbon sites, as will be understood by one skill in the art. The
atom/compound bridging the aryl/phenyl groups may be carbon, oxygen, sulfur, nitrogen, or derivative of carbon, oxygen, sulfur, or nitrogen.

Use of Preferred Compositions as Enzyme Inhibitors
Human "carbonyl reductase" is believed to comprise several isoenzymes, which are members of the short-chain dehydrogenase/reductase superfamily and monomeric or tetrameric with subunit molecular weight of approximately 30
kDa. Carbonyl reductase uses NAD PH, and may have physi010gica roles including quinone detoxification or other roles.
Multiple studies point to human carbonyl reductase (such
as carbonyl reductase 1) having a role in the production of the
anthracycline metabolites believed to cause cardiotoxic side
effects in cancer patients either near the time of the chemotherapy or at some later time. This disease or condition of
cardiotoxicity related to anthracycline drugs is briefly
described above in the Related Art Section. Also, see FIG. 2
for one example of a mechanism of carbonyl reductase reduction of an anti-cancer anthracycline to a cardiotoxic alcohol
metabolite. C13-hydroxy-metabolites are believed to be the
principle cardiotoxic agents resulting from enzyme action
upon anthracyclines.

40

45
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for improving efficacy of drugs used in cancer treatment offor
treating or preventing side effects of cancer treatment or
cardiotoxicity. Further, to the inventors' knowledge, triclosan, hexachlorophene, or dichlorophene have not been
previously reported as carbonyl reductase inhibitors. The
inventors believe that said effective and safe doses may be
found without undue experimentation by one of skill in the art
after reading this disclosure, especially in view of literature
regarding known uses (as anti-biotics and anti-neoplastic
agents) of triclosan, hexachlorophene, and dichlorophene.
In use, one or more of the preferred compounds, triclosan,
hexachlorophene, dichlorophene and compounds with the
biphenyl compound core or "general" structure (FIG. 3F)
may be used in a pharmaceutical composition, which may
also comprise one or more of the anthracycline drugs and/or
other chemotherapy drugs or other medicines that may be
beneficial to the cancer patient. Preferably, the triclosan,
hexachlorophene, dichlorophene and compounds with the
biphenyl compound core structure (FIG. 3F) and anthracycline compositions are given at levels that produce the desired
anti-cancer effects without the cardiotoxicity side effects.
Therefore, the relative compositions may be changed for
different anthracyclines and/or for different patients and/or
for different cancers. The methods include treatment of, or
treatment of side effects, for all cancers for which anthracyclines are used. Embodiments of the invention therefore
include a pharmaceutical composition comprising at least one
anthracycline compound and triclosan, hexachlorophene,
dichlorophene and compounds with the general core structure
depicted in FIG. 3F or a mixture of some or all thereof. The
inventor envisions that there may be analogs or derivatives of
triclosan, hexachlorophene, dichlorophene and compounds
with the biphenyl compound core structure (FIG. 3F) that also
may be effective in compositions and methods of the invention. For example, the compositions may include anthracycline compounds selected from the group consisting of adriamycinldoxorubicin, daunorubicinldaunomycin, epirubicin,
idarubicin, and a mixture of two or more thereof.
While the preferred patients are humans, animals may also
benefit from the compositions and methods. Embodiments of
the invented method may be for preventing or treating cardiotoxicity associated with anthracycline cancer chemotherapy in a mammal in need thereof, wherein the method
comprises administering to the mammal a composition comprising an effective amount of a pharmaceutical composition
comprising at least one anthracycline compound and at least
one compound or mixture selected from the group consisting
of triclosan, hexachlorophene, dichlorophene, compounds
with the biphenyl compound core structure (FIG. 3F), a mixture of some of all of said compounds, an analog and/or
derivative of said compounds, and mixtures of two or more
thereof. Effective amounts will be determined by methods
known to those of skill in the art. Examples of anthracycline
compounds include adriamycinldoxorubicin), daunorubicinl
daunomycin, epirubicin, idarubicin, and a mixture of two or
more thereof.
Instead of, or in addition to, administering a pharmaceutical composition including both anthracycline(s) and triclosan, hexachlorophene, dichlorophene and compounds
with the biphenyl compound core structure (FIG. 3F), separate pharmaceutical compositions may be used. For example,
methods may include preventing or treating a disease or condition associated with carbonyl reductase in a mammal in
need thereof by administering to the manm13l a first pharmaceutical composition comprising at least one anthracycline
compound; and also administering to the mammal a second
pharmaceutical composition comprising triclosan, hexachlo-

rophene, dichlorophene and compounds with the biphenyl
compound core structure (FIG. 3F), or a mixture of some or
all thereof. The first and second pharmaceutical compositions
may be administered at the same time, or may be administered at nearly the same time (for example, within 15 minutes
or less), or preferably within a few hours of each other (for
example, within 2 hours or less). It may be beneficial to treat
the patient with triclosan, hexachlorophene, dichlorophene,
and/or compounds with the biphenyl compound core structure (FIG. 3F) prior to anthracycline therapy (for example,
two hours or less prior to anthracycline treatment), to block
carbonyl reductase before administration of the anthracycline
drug(s).
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Inhibition Data
Triclosan, hexachlorophene, and dichlorophene were
tested as possible inhibitors for carbonyl reductase. Triclosan
and hexachlorophene (See FIGS. 3C and E) were found to be
uncompetitive inhibitors against the carbonyl substrate, with
triclosan being one of the most potent carbonyl reductase
inhibitors known to date. Dichlorophene (See FIG. 3D) was
found to be a noncompetitive inhibitor of carbonyl reductase
at 50 flM NADPH and an uncompetitive inhibitor at 300 flM
NADPH. See FIG. 4-6, portraying the lIratevs. lImenadione
concentration studies done with dichlorophene, hexachlorophene, and triclsosan, respectively. The data in FIGS. 4-6
show changes in y-intercept, while only the data in FIG. 4,
show changes in slope. To those skilled in the art, it will be
evident that dichlorophene exhibits noncompetitive inhibition against menadione, while hexachlorophene and tricosan
exhibit uncompetitive inhibition against varied menadione.
As shown in FIG. 7, triclosan has the lowest inhibition constant (0.23 flM) and is therefore the over 52 times more potent
in its inhibition than is hexachlorophene. Therefore, while
compositions comprising triclosan are preferred, compositions comprising hexachlorophene and dichlorophene are
also included in embodiments of the invention and are also
expected by the inventors to be beneficial in the methods of
the invention. The inhibition patterns noted in FIG. 7 are
further described/explained as follows:
a. Regarding note "a" in FIG. 7: Studies were done with a
fixed NADPH concentration of flM 50, varied menadione
concentrations ranging from 12 to 125 flM in 100 mM sodium
phosphate buffer, pH=7.0.
b. Regarding note "b" in FIG. 7: The data fit best to the
uncompetitive inhibition model

50

55

wherein A is the concentration of menadione, I is the inhibitor
concentration, V is the maximal velocity, Km is the Michaelis
constant for mendadione and Kii is the intercept inhibition
constant.
c. Regarding note "c" in FIG. 7: The data fit best to the
noncompetitive inhibition model

60
VA

65

wherein A is the concentration of menadione, I is the inhibitor
concentration, V is the maximal velocity, Km is the Michaelis
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constant for menadione, Kii is the intercept inhibition constant, and K is is the slope inhibition constant.
d. Regarding note "d" is FIG. 7: The study was done with
a fixed NADPH concentration of 300 flM and varied menadione as described above.
From the above inhibition patterns, the inhibitors triclosan,
hexachlorophene, and dichlorophene most likely bind to the
free enzyme and!orthe enzyme-NADP+ binary complex and!
or the enzyme-menadione-NADPH ternary complex, as illustrated in FIG. S. It is expected that substrate carbonyls should
not appreciably compete against the preferred inhibitors at
these sites. Thus, said preferred inhibitors according to the
invention are expected to remain available for, and will effectively carry out, inhibition of the mechanism that would otherwise result in lower efficacy of anthracycline(s) drugs and
in cardiotoxic compounds.
In a breast cancer cell line, MDA, triclosan was shown to
decrease the doxorubicin IC so for cell killing. It appears from
the graph in FIG. 9, that it is possible to increase the cell
killing efficacy of doxorubicin by about 4-fold in breast cancer cells. FIG. 9 illustrates the large decrease in IC so ofDoxorubicin when 40 flM triclosan is used compared to 0 (zero) flM
triclosan (approximately 380 nM reduced to approximately
145 nM), and the additional but smaller decrease in IC so of
Doxorubicin when 60 flM triclosan is used compared to 40
flM triclosan (approximately 145 nM reduced to approximately 95 nM), and the additional but even smaller decrease
in IC so of Doxorubicin when 80 flM triclosan is used (approximately 95 nM reduced to approximately 85 nM). The
reduction in IC so for doxorubicin appears to have a lower
limit of about 85 nM when 80 flM triclosan is used.
Although this invention has been described above with
reference to particular means, materials and embodiments, it
is to be understood that the invention is not limited to these
disclosed particulars, but extends instead to all equivalents
within the broad scope of the following claims.

3. A method for reducing effective doses of anthracycline
effective for cancer chemotherapy in a human in need thereof,
the method comprising:
administering to the human a composition comprising an
effective amount of a pharmaceutical composition comprising at least one anthracycline compound selected
from the group consisting of adriamycin, daunomycin,
daunorubicin, doxorubicin, epirubicin, idarubicin, and
mixtures of two or more thereof, and at least one enzyme
inhibitor lowering effective doses of anthracycline, said
at least one enzyme inhibitor comprising a human carbonyl reductase enzyme inhibitor selected from the
group consisting oftriclosan, hexachlorophene, dichlorophene, and mixtures of two or more thereof, and
exhibits a KII value in the range of 0.23-78 microMolar.
4. The method of claim 3, further comprising reducing
cardiotoxicity associated with anthracycline cancer chemotherapy by means of said at least one enzyme inhibitor inhibiting human carbonyl reductase.
5. A method for improving efficacy of anthracycline chemotherapy by inhibiting carbonyl reductase in a human, the
method comprising:
administering to the human a first pharmaceutical composition comprising at least one anthracycline compound
selected from the group consisting of adriamycin,
daunomycin, daunorubicin, doxorubicin, epirubicin,
idarubicin, and mixtures of two or more thereof; and,
also administering to the human a second pharmaceutical
composition comprising an enzyme inhibitor comprising at least one carbonyl reductase enzyme inhibitor
compound, wherein said at least one carbonyl reductase
enzyme inhibitor compound is selected from the group
consisting of triclosan, hexachlorophene, dichlorophene, and mixtures of two or more thereof, and
wherein said at least one enzyme inhibitor exhibits a KII
value in the range of 0.23-78 micro Molar.
6. A method as in claim 5, wherein said second pharmaceutical composition is administered at the same time as said
first pharmaceutical composition.
7. A method as in claim 5, wherein said second pharmaceutical composition is administered within two hours or less
of said first pharmaceutical composition.
S. A method as in claim 5, wherein said second pharmaceutical is administered prior to the first pharmaceutical composition.
9. A method as in claim 5, wherein said second pharmaceutical is administered after the first pharmaceutical composition.

The invention claimed is:
1. A pharmaceutical composition comprising at least one
anthracycline compound selected from the group consisting
ofadriamycin, daunomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, and mixtures of two or more thereof, and
at least one carbonyl reductase enzyme inhibitor compound
selected from the group consisting of triclosan, hexachlorophene, dichlorophene, and mixtures of two or more thereof,
and wherein said at least one enzyme inhibitor exhibits a KII
value in the range of 0.23-78 microMolar.
2. A composition as in claim 1 wherein said carbonyl
reductase inhibitor compound is triclosan and exhibits a KII
value of 0.23 microMolar.
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